Multiple sclerosis - The treatment options

Hospital Pharmacist

Volumn 10, Issue 1, 2003, Pages 17-21

  Reed, Claire ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID DERIVATIVE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AZATHIOPRINE; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CLONAZEPAM; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANTROLENE; DIAZEPAM; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; ISONIAZID; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NEUTRALIZING ANTIBODY; ONDANSETRON; PREDNISOLONE; SALAZOSULFAPYRIDINE; SPASMOLYTIC AGENT; STEROID; TIZANIDINE; UNINDEXED DRUG;

ANTIBODY RESPONSE; ANXIETY; ARTHRALGIA; CARDIOTOXICITY; CHILL; CONFUSION; DISEASE EXACERBATION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; FEVER; FLU LIKE SYNDROME; FLUSHING; HALLUCINATION; HEADACHE; HEART PALPITATION; HUMAN; INFECTION; INJECTION SITE; LIVER TOXICITY; MALAISE; MEDICAL SOCIETY; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; MYALGIA; PALLIATIVE THERAPY; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PSYCHOSIS; REBOUND; REVIEW; SEDATION; SEIZURE; SEPTICEMIA; SIDE EFFECT; SPASTICITY; SWEATING; SYMPTOM; SYMPTOMATOLOGY; TACHYCARDIA; THORAX PAIN; TREMOR;

EID: 0037231268     PISSN: 13527967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Green B, Mynes S. Issues in MS. Pharm J 1999;262:699-701.
2. Clegg A, Bryant J, Milne R. Disease modifying drugs for multiple sclerosis: a rapid systematic review. Health Technology Assessment 2000;4:1.
3. Hartnung HP, Gonsette R. MIMS Study Group. Mitoxantrone in progressive multiple sclerosis. A placebo-controlled, randomised, observer-blind European phase III multicentre study - clinical results (abstract OR 207). Multiple Sclerosis 1998;4:325.
4. Toosy A, Thompson A. Multiple sclerosis: the disease and its treatment. Pharm J 2000;264:694-700.
5. Beck RW, Cleary PA, Anderson MMJ, Keltner JL, Shults WT, Kaufman DI et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The optic neuritis study group. N Engl J Med 1992;326:581-8.
6. Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1998;51:529-34.
7. Technology Appraisal Guidance number 32. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. London: National Institute for Clinical Excellence; 2002 (January).
8. Association of British Neurologists. Guidelines for the use of beta interferon in multiple sclerosis. London: Association of British Neurologists; 1999.
9. Health Service Circular 2002/04. Cost effective provision of disease modifying therapies for people with multiple sclerosis. London: Department of Health; 2002.
10. Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RA, McPherson K et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991;338:1051-5.
11. Noseworthy JH, Gold R, Hartung H. Treatment of multiple sclerosis: recent trials and future perspectives. Curr Opin Neurol 1999;12:279-93.
12. Bryant J, Clegg A, Milne R. Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost? J Neurol Neurosurg Psychiatry 2001;70:574-9.
13. Association of British Neurologists. Guidelines on intravenous immunoglobulins (IVIgs). London: Association of British Neurologists; 2001.
14. Mitoxantrone receives multiple sclerosis licence. Am J Hosp Pharm 2000;57:2039-40.
15. Richards RG, Sampson FC, Beard SM, Tappenham P. A review of the natural history and epidemiology of multiple sclerosis. Implications for resource allocation and health economic models. Health Technology Assessment 2002;6:9.
16. Morrow J, McDowell H, Ritchie C, Patterson V. Isoniazid and action tremor in multiple sclerosis. J Neurol Neurosurg Psychiatry 1985;48:282-3.
17. Hallet M, Lindsey JW, Adelstein BD, Riley PO. Controlled trial of isoniazid therapy for severe postural cerebellar tremor in multiple sclerosis. Neurology 1985;35:1374-7.
18. 3 antagonist, improves cerebellar tremor. J Neurol Neurosurg Psychiatry 1997;62:282-4.
19. Rice GP, Lesaux J, Ebers G. Ondansetron versus placebo for disabling cerebellar tremor: final report of a randomised clinical trial. Ann Neurol 1999;46:493.
20. Brañas P, Jordan R, Fry-Smith A, Burls A, Hyde C. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technology Assessment 2000;4:
21. Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L et al. Fatigue therapy in multiple sclerosis: results of a double blind, randomised, parallel trial of amantadine, pemoline and placebo. Neurology 1995;45:1956-61.
22. Weinshenker BG, Penman M, Bass B, Ebers GC, Rice GP. A double blind, randomised, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992;42:1468-71.
23. Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4-Aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol 1994;51:292-6.
24. Sheean GL, Murray NM, Rothwell JC, Miller DH, Thompson AJ. An open-labelled clinical and electrophysiological study of 3,4- diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain 1998;121:967-75.
25. Duvensky A, Perel AB. Gabapentin for relief of spasticity associated with multiple sclerosis. Am J Phys Med Rehab 1998;77:451-4.
26. Williamson E, Evans F. Cannabinoids in clinical practice. Drugs 2000;60:1303-14.
27. Rudick KA, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM. Management of multiple sclerosis. N Engl J Med 1997;337:1604-11.
28. Whitlock FA, Siskind MM. Depression as a major symptom of multiple sclerosis. J Neurol Neurosurg Psychiatry 1980;43:861-5.